image
Communication Services - Publishing - NYSE - GB
$ 15.795
-0.825 %
$ 10.7 B
Market Cap
18.61
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PSO stock under the worst case scenario is HIDDEN Compared to the current market price of 15.8 USD, Pearson plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PSO stock under the base case scenario is HIDDEN Compared to the current market price of 15.8 USD, Pearson plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PSO stock under the best case scenario is HIDDEN Compared to the current market price of 15.8 USD, Pearson plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PSO

image
$18.0$18.0$17.5$17.5$17.0$17.0$16.5$16.5$16.0$16.0$15.5$15.5$15.0$15.0$14.5$14.5$14.0$14.0$13.5$13.5Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
3.55 B REVENUE
-3.32%
541 M OPERATING INCOME
8.63%
510 M NET INCOME
34.92%
627 M OPERATING CASH FLOW
19.43%
-131 M INVESTING CASH FLOW
56.48%
-241 M FINANCING CASH FLOW
46.44%
1.75 B REVENUE
-2.28%
219 M OPERATING INCOME
-22.34%
157 M NET INCOME
-18.23%
75 M OPERATING CASH FLOW
-90.88%
-81 M INVESTING CASH FLOW
77.93%
36 M FINANCING CASH FLOW
107.21%
Balance Sheet Pearson plc
image
Current Assets 2.73 B
Cash & Short-Term Investments 543 M
Receivables 0
Other Current Assets 2.18 B
Non-Current Assets 4.16 B
Long-Term Investments 0
PP&E 216 M
Other Non-Current Assets 3.95 B
7.88 %31.70 %3.13 %57.28 %Total Assets$6.9b
Current Liabilities 1.48 B
Accounts Payable 273 M
Short-Term Debt 315 M
Other Current Liabilities 890 M
Non-Current Liabilities 1.36 B
Long-Term Debt 1.16 B
Other Non-Current Liabilities 204 M
9.62 %11.10 %31.35 %40.75 %7.19 %Total Liabilities$2.8b
EFFICIENCY
Earnings Waterfall Pearson plc
image
Revenue 3.55 B
Cost Of Revenue 1.74 B
Gross Profit 1.81 B
Operating Expenses 1.27 B
Operating Income 541 M
Other Expenses 31 M
Net Income 510 M
4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(2b)2b(1b)541m(31m)510mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
50.99% GROSS MARGIN
50.99%
15.23% OPERATING MARGIN
15.23%
12.22% NET MARGIN
12.22%
10.75% ROE
10.75%
6.30% ROA
6.30%
8.05% ROIC
8.05%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pearson plc
image
600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 510 M
Depreciation & Amortization 526 M
Capital Expenditures -124 M
Stock-Based Compensation 44 M
Change in Working Capital -53 M
Others -500 M
Free Cash Flow 503 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pearson plc
image
Wall Street analysts predict an average 1-year price target for PSO of $14.5 , with forecasts ranging from a low of $11 to a high of $18 .
PSO Lowest Price Target Wall Street Target
11 USD -30.36%
PSO Average Price Target Wall Street Target
14.5 USD -8.20%
PSO Highest Price Target Wall Street Target
18 USD 13.96%
Price
Max Price Target
Min Price Target
Average Price Target
18181717161615151414131312121111Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.209 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.0000001.0000000.9000000.9000000.8000000.8000000.7000000.7000000.6000000.6000000.5000000.5000000.4000000.4000000.3000000.3000000.2000000.2000000.1000000.1000000.0000000.0000000.1740.188510.18940.181510.198680.209160.5250.4810.42360.16660.1710.2810.980.2380.910.0650.680.07190.420.0730.440.07780.290.0875440.090.0810.080.0864710.090.0949710.090.002015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Pearson plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Certifications Fuel Success in the Age of AI: Pearson Releases the 2025 Value of IT Certification Candidate Report SAN DIEGO , April 9, 2025 /PRNewswire/ -- Pearson (FTSE: PSON.L) and its Pearson VUE business, the global leader in computer-based testing, released their newest Value of IT Certification Candidate Report. This comprehensive study, the ninth in an ongoing series, provides crucial insights into the evolving landscape of IT certification and its impact on professionals and organizations worldwide. prnewswire.com - 3 weeks ago
Pearson Redefines its Brand to Embrace the Future of Learning New brand identity reflects learning as a core human need, essential for personal happiness and progress LONDON , April 7, 2025 /PRNewswire/ -- Pearson (FTSE: PSON.L), the world's leading learning company, today unveiled a dynamic new brand identity that demonstrates its leadership as a lifelong learning company. More than just a refreshed logo, the rebrand represents a deep understanding of the evolving needs of learners worldwide. prnewswire.com - 3 weeks ago
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome MNV-201 is Minovia's second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare Pediatr i c Designation granted MNV-201 is also being studied in a Phase Ib for low-risk Myelodysplastic Syndrome; Preliminary clinical data demonstrate safety and efficacy HAIFA, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd, a clinical stage biopharmaceutical company advancing mitochondrial therapies for primary and secondary mitochondrial diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its second Investigational New Drug (IND) application for MNV-201 , an autologous hematopoietic stem cell product augmented with allogeneic mitochondria . The IND supports the initiation of a Phase I I clinical trial of MNV-201 in pediatric patients with Pearson Syndrome, a primary mitochondrial disease. globenewswire.com - 4 weeks ago
ExtensisHR's David R. Pearson Honored as CHRO of the Year by C-Suite Insider WOODBRIDGE, N.J.--(BUSINESS WIRE)-- #HR--ExtensisHR's David R. Pearson has been named “CHRO of the Year (PEO & HRO) – New Jersey 2025” by C-Suite Insider. businesswire.com - 1 month ago
Pearson Announces Newly Expanded Role for Chief Technology Officer, Dave Treat, as Company Further Scales AI and Tech Capabilities Dave Treat to lead Pearson's digital and technology operation, expanding his current architectural and innovation responsibilities LONDON , March 31, 2025 /PRNewswire/ -- Pearson (FTSE: PSON.L), the world's lifelong learning company, announced today that Dave Treat, Pearson's Chief Technology Officer, will assume leadership of the company's digital and technology operation alongside his current architectural and innovation responsibilities, effective April 7. Dave will continue to report to CEO Omar Abbosh and retain his title of Chief Technology Officer. prnewswire.com - 1 month ago
Pearson Expands Professional Learning Capabilities with New Skilling Partner Program 4,600+ Pearson VUE third-party test centers worldwide can now add training to career certification services - creating one-stop learning and certification hubs; addresses the global skills gap LONDON , March 31, 2025 /PRNewswire/ -- Pearson (FTSE: PSON.L), the world's leading learning company, today launched its Pearson Skilling Partner  program, expanding its ability to deliver comprehensive skills training and career certification solutions worldwide. As AI and technology reshape industries at a breathtaking pace, people around the globe must continuously develop new skills. prnewswire.com - 1 month ago
Best Momentum Stock to Buy for March 17th PSO, VEEV and PAA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 17, 2025. zacks.com - 1 month ago
Dividend Watch: 2 Top Ranked Companies Boosting Payouts Companies commonly boost payouts when business is fruitful, overall sending a positive message concerning the longer-term picture. zacks.com - 1 month ago
3 Media Stocks to Watch From a Challenging Industry Zacks Media Conglomerates industry players like PSO, PARA and RSVR gain from the rising demand for high-speed Internet and increased media consumption. zacks.com - 1 month ago
Pearson Announces Arden Hoffman as Non-Executive Director LONDON , March 7, 2025 /PRNewswire/ -- Pearson (FTSE: PSON.L), the world's lifelong learning company, today announces the appointment of Arden Hoffman as an independent Non-Executive Director, with effect from 1 June 2025. Arden has held significant leadership positions within high-profile organisations and brings to Pearson a strong expertise and business perspective on workforce and talent development in an era of innovation and AI. prnewswire.com - 1 month ago
Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. PGR, PSO, TXO & JAZZ are well-poised to gain. zacks.com - 1 month ago
AI Isn't Enough: Why Pearson's Stock Looks Overvalued And Vulnerable Pearson plc's Q4 earnings showed a 10% profit boost and a 16.9% EBIT margin, but competitive pressures and macroeconomic risks loom large. The company's AI integration and partnerships with AWS and Microsoft aim to enhance digital learning, yet the valuation appears overly optimistic. Despite strong business momentum, Pearson's reliance on a strong H2 2025 and declining free cash flow raise concerns about long-term growth. seekingalpha.com - 1 month ago
8. Profile Summary

Pearson plc PSO

image
COUNTRY GB
INDUSTRY Publishing
MARKET CAP $ 10.7 B
Dividend Yield 0.00%
Description Pearson plc provides educational courseware, assessments, and services in the United Kingdom, the United States, Canada, the Asia Pacific, other European countries, and internationally. It operates through five segments: Assessment & Qualifications, Virtual Learning, English Language Learning, Higher Education, and Workforce Skills. The Assessment & Qualifications segment offers Pearson VUE, US student assessment, clinical assessment, UK GCSE, and A levels and international academic qualifications. The Virtual Learning segment provides virtual schools and online program management services. The English Language Learning segment offers Pearson test of English, institutional courseware, and English online solutions. The Higher Education segment provides the US, Canadian, and international higher education courseware businesses. The Workforce Skills offers BTEC, GED, TalentLens, Faethm, Pearson college, and apprenticeships. Pearson plc was founded in 1844 and is headquartered in London, the United Kingdom.
Contact 80 Strand, London, WC2R 0RL https://plc.pearson.com
IPO Date Nov. 18, 1996
Employees 17116
Officers Ms. Allison P. Bebo Chief Human Resources Officer Mr. Robert Whelan President of Assessments & Qualifications Ms. Ginny Cartwright Ziegler Chief Marketing Officer Mr. Tim Bozik President of Higher Education, Interim Chief Product Officer & Co-President of Direct to Consumer Ms. Cinthia Nespoli General Counsel & Executive Leader for Sustainability Ms. Sally Kate Miranda Johnson Chief Financial Officer & Executive Director Mr. Dave Treat Chief Technology Officer Mr. Albert Roger Hitchcock Head of Telecom & Technology Partnerships Mr. Cedrick Collomb Senior Vice President for Global Product Technology Mr. Omar Paul Abbosh Chief Executive Officer & Executive Director